In this phase, melanoma cells reshape their immunologic features when in interactions with immune cells, including the downregulation of tumor-associated antigens (TAAs) and MHC molecules; the deletion in antigen-processing machinery; the upregulation of immune checkpoints PD-L1, TIM-3, and LAG-3; and the secretion of chemokines and cytokines, and finally result in melanoma immune escape (36, 37). The gene discussed is HAVCR2; the disease is melanoma.